Your browser doesn't support javascript.
loading
Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells.
Revalde, Jezrael L; Li, Yan; Wijeratne, Tharaka S; Bugde, Piyush; Hawkins, Bill C; Rosengren, Rhonda J; Paxton, James W.
Afiliación
  • Revalde JL; Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
  • Li Y; School of Interprofessional Health Studies, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand. Electronic address: yali@aut.ac.nz.
  • Wijeratne TS; Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
  • Bugde P; School of Interprofessional Health Studies, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand.
  • Hawkins BC; Department of Chemistry, University of Otago, Dunedin, New Zealand.
  • Rosengren RJ; Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.
  • Paxton JW; Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Eur J Pharmacol ; 803: 167-173, 2017 May 15.
Article en En | MEDLINE | ID: mdl-28365185
ABSTRACT
Our group investigated combining the phytochemical curcumin and gemcitabine in a liposome, to improve gemcitabine's activity against pancreatic tumours. While optimising the curcumin gemcitabine ratio for co-encapsulation, we found that increasing curcumin concentrations relative to gemcitabine resulted in antagonistic interactions. As curcumin is a promiscuous transporter inhibitor; we suspected that increased resistance occurred via inhibition of Equilibrative nucleoside transporter 1 (ENT1)-mediated gemcitabine uptake. To test our hypothesis, we determined whether curcumin and a related analogue, 2,6-bis((3-methoxy-4-hydroxyphenyl)methylene)-cyclohexanone (or A13), inhibited ENT1-mediated accumulation of [3H]uridine and [3H]gemcitabine into pancreatic cancer cells. We then confirmed the inhibition of gemcitabine accumulation by investigating whether curcumin/A13 could increase gemcitabine resistance in growth inhibition assays. We found that curcumin and A13 concentration-dependently inhibited the ENT1-mediated accumulation of both uridine and gemcitabine in MIA PaCa-2 and PANC-1 cells. We also found that non-toxic concentrations of curcumin and A13 significantly increased the resistance of both cell lines to gemcitabine. Increased resistance only occurred when curcumin/A13 was co-incubated with gemcitabine, and not with sequential exposure (i.e., curcumin first, followed by gemcitabine, or vice versa). We also found that the curcumin analogue (3E,5E)-3,5-bis[(2-fluorophenyl)methylene]-4-piperidinone (or EF24) did not inhibit gemcitabine accumulation, making it more suitable in combinations than curcumin/A13. From these results, we concluded that curcumin and A13 are inhibitors of the ENT1 transporter, but only at high concentrations (2-20µM). Curcumin is unlikely to inhibit gemcitabine uptake in tumours but may interfere with the oral absorption of ENT1 substrates due to high gut concentrations readily achievable from over-the-counter tablets/capsules.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Curcumina / Ciclohexanonas / Tranportador Equilibrativo 1 de Nucleósido / Antineoplásicos Límite: Humans Idioma: En Revista: Eur J Pharmacol Año: 2017 Tipo del documento: Article País de afiliación: Nueva Zelanda

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Curcumina / Ciclohexanonas / Tranportador Equilibrativo 1 de Nucleósido / Antineoplásicos Límite: Humans Idioma: En Revista: Eur J Pharmacol Año: 2017 Tipo del documento: Article País de afiliación: Nueva Zelanda